

Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSE

Dr. Sofocleous is a professor of Radiology at Weill-Cornell Medical College of Cornell University, practicing interventional oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York city since 2002. He is a world-renowned interventional oncologist a founding member and one of the directors at large of the Society of Interventional Oncology (SIO). He was the chair of the 2016 World Conference of Interventional Oncology (WCIO) and he serves as the international liaison of the annual meeting committee of the Society of interventional Radiology (SIR). He is a fellow of the SIR and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

His work on interventional oncology covers a wide range of image-guided procedures. Dr. Sofocleous is an opinion leader and worldwide expert on image guided therapies for metastatic disease especially colorectal cancer hepatic and pulmonary metastases. His dedication in research and promotion of knowledge through medical investigation have resulted in over 151 peer-reviewed publications and a scopus author citation index of over 4450 as of December 31, 2018. His contributions in the field of interventional oncology have been recognized nationally and internationally as indicated through the numerous invited lectures that he has delivered throughout the world, as well as his leadership roles in the Society of Interventional Radiology (SIR), the National Comprehensive Cancer Network (NCCN) the newly created Society of Interventional Oncology and the Radiological Society of Northern America (RSNA).

Dr. Sofocleous is a strong believer in multidisciplinary work and integration not only in the clinical but also the research field. He believes that progress and excellence in the fight against cancer will come through interdisciplinary work and collaboration in all fronts. Through collaboration with medical and surgical oncology; molecular cytology and metabolic imaging experts he was able to receive NIH funding allowing him to investigate the cellular and immunohistochemical changes of tumors undergoing thermal ablation. Exploring tissue and surrogate imaging biomarkers was one of the main aims in this initial work that resulted in landmark publications establishing the relation between biomarkers and ablation technique to oncologic outcomes in patients with cancer treated with ablation. It is noteworthy to mention that this work explored and validated the use of fluorescent stains in solid tissue for the first time, indicating their potential use as an immediate intraprocedural tool of ablation treatment success or failure. His work aspires to change the ablation treatment paradigm through clinical trials incorporating immediate tissue examinations with real-time metabolic and anatomic imaging as well as genetic tumor analyses for colon cancer liver metastases. Over the years and through close clinical collaboration with medical, surgical and radiation oncology his work focused more and more in the management of oligometastatic disease and in particular colorectal cancer, though imaging-guided interventions such as ablation and Yttrium 90 Radioembolization. In addition to his work in tumor ablation, he was able to investigate the use of Y90 radioembolization (TARE) in the management of colorectal cancer (CRC) liver metastases that progressed after surgery, ablation and hepatic arterial chemotherapy. His work was important to establish the safety of TARE in heavily pretreated populations with liver dominant metastatic disease, currently recommended through the NCCN guidelines for selected CRC patients. Several subsequent investigations in this field further established his position as an opinion thought leader and led to further industrial funding. Dr. Sofocleous is the MSKCC cite PI of an ongoing international randomized controlled study assessing oncologic outcomes of combining glass Yttrium microspheres with second line chemotherapy in the treatment of colon cancer liver metastases.